This disclosure relates to an agent consisting of theobromine and either an expectorant or a mucolytic to use in the therapy of a cough. The expectorant may be ambroxol, ammonium bicarbonate, ammonium carbonate, bromhexine, calcium iodide, carbocysteine, guaiacol, guaicacol benzoate, guaiacol carbonate, guaiacol phosphate, guaifenesin, guaithylline, hydriodic acid, iodinated glycerol, potassium guaiacolsulfonate, potassium iodide, sodium citrate, sodium iodide, 20 storax terebene, terpin, trifolium, althea root, antimony pentasulfide, creosote, Ipecacuanha (syrup of ipecac), levoverbenone, senega or tyloxapol and the mucolytic may be acetylcysteine, 25 bromhexine, carbocysteine, domiodol, erdostine, letostine, lysozyme, mecysteine hydrochloride, mesna, sobrerol, stepronin, tiopronin, tyloxapol, ambroxol, ammonium chloride, dornase alfa, eprazinone, erdosteine, letosteine or neltenexine.
